Zenas BioPharma, Inc. (ZBIO) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Zenas BioPharma, Inc. (ZBIO) trades at a price-to-earnings ratio of -2.1x, with a stock price of $17.76 and trailing twelve-month earnings per share of $-7.64.
Compared to the Healthcare sector median P/E of 23.1x, ZBIO trades at a 109% discount to its sector peers. The sector includes 235 companies with P/E ratios ranging from 0.0x to 187.5x.
Relative to the broader market, ZBIO trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZBIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZBIO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ZBIO P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 31.4 | - | -34% | |
| $8B | 27.6 | 1.20 | -25% | |
| $4B | 9.3 | - | +68% | |
| $2B | 6.8Lowest | 0.66Best | +817%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
What if you invested $1,000 in ZBIO back in 2026?
Total return with dividends reinvested · 0+ years of data
Calculate ReturnsHow much would $100/month in ZBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ZBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationZBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowZBIO — Frequently Asked Questions
Quick answers to the most common questions about buying ZBIO stock.
What is ZBIO's P/E ratio?
Zenas BioPharma, Inc. (ZBIO) trailing twelve-month P/E ratio is -2.1x, based on TTM diluted EPS of $-7.64. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is ZBIO stock overvalued or undervalued?
ZBIO current P/E: -2.1x. 5-year average P/E: N/A. Percentile: N/A.
Is ZBIO stock expensive?
ZBIO is fairly valued relative to its own history. The current P/E of -2.1x is near the 5-year average of N/A (N/A percentile of historical range).
What is ZBIO's historical P/E range?
Over the past 5 years, ZBIO's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -2.1x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does ZBIO's P/E compare to the S&P 500?
ZBIO trades at -2.1x P/E versus the S&P 500 median of 24.9x. The 108% discount to the market suggests lower growth expectations or perceived higher risk.
How does ZBIO's valuation compare to Healthcare peers?
Zenas BioPharma, Inc. P/E of -2.1x compares to the Healthcare sector median of 23.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ZBIO's PEG ratio?
ZBIO PEG ratio is N/A, based on a P/E of -2.1x and EPS growth of -124.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ZBIO's earnings yield?
ZBIO earnings yield is N/A, the inverse of its -2.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.